Akoya Biosciences
Investment firm Kent Lake said the securities deal, which is linked to the firm's planned acquisition of Akoya, is "backdoor financing" and "highly unfavorable to Quanterix shareholders."
Major Quanterix Investor Opposes $30M Akoya Securities Purchase Agreement
Investment firm Kent Lake said the deal, which is linked to the firm's planned acquisition of Akoya, is "backdoor financing" and "highly unfavorable to Quanterix shareholders."
In Brief This Week: Beckman Coulter, Quest Diagnostics, Guardant Health, Diasorin, More
News items for the week of Jan. 27, 2025.
Top Five Articles on 360Dx Last Week: Sepsis Testing in 2024; FDA Guidance on Test Validation; More
Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.
Quanterix to Acquire Akoya Biosciences
The deal will integrate Akoya's spatial biology capabilities with Quanterix's biomarker-detection tools for ultra-sensitive detection of protein biomarkers in blood and tissue.